Palisade Bio, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Palisade Bio, Inc. (Nasdaq: PALI) Palisade Bio, Inc. is a clinical-stage biopharmaceutical company that develops and advances novel oral therapeutics targeting autoimmune, inflammatory and fibrotic diseases, with a focus on inflammatory bowel disease indications including moderate-to-severe ulcerative colitis and fibrostenotic Crohn's disease. The company's lead product candidate, PALI-2108, comprises a locally bioactivated PDE4 inhibitor prodrug designed for once-daily oral administration to achieve sustained localized activation, low systemic exposure and controlled release within the gastrointestinal tract; it has demonstrated 100% clinical response in a Phase 1b ulcerative colitis cohort with favorable tolerability, and advances toward a Phase 2 trial evaluating clinical remission, response and pharmacodynamic biomarkers over 12 weeks plus a maintenance extension, alongside planned fibrostenotic Crohn's disease studies. Palisade Bio leverages a proprietary prodrug platform via an exclusive worldwide license from Giiant Pharma, Inc. for precision delivery technology and related compounds including rights to GT-2108 and GT-1908; it maintains a research collaboration and license agreement with the Regents of the University of California, as well as a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Founded in 1996 and headquartered in Carlsbad, California, the company operates primarily in the United States with global intellectual property protections such as a recent patent allowance in China for PALI-2108 extending to 2045. Recent developments include the closing of an upsized $138 million public offering of common stock in October 2025 with full exercise of the over-allotment option to fund pipeline advancement and operations; an agreement in July 2025 for the exercise of existing warrants raising approximately $3.9 million in gross proceeds; and a significant 9.99% stake acquisition by Perceptive Advisors LLC reported in October 2025.
Company News
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.83 According to Analysts
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Palisade Bio to Participate in Upcoming Investor Conferences
Brokerages Set Palisade Bio, Inc. (NASDAQ:PALI) Price Target at $9.00
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium